Bicalutamide,Abiraterone,Apalutamide
Janssen
['biomarker', 'marker ']
 . i feel all of those papers explaining problems with dfs are read selectively. just glad reads them. dfs in setting of adt very problematic. you are in inhibiting the biomarker that drives the endpoint not necessarily patient benefit
Vincent Smith Professor and Chair of Radiation Oncology University Hospitals Seidman Cancer Center Case Western Reserve University SOM.  *TWEETS are my own*